PSC Australia
  • Home
  • PSC
  • Resources
  • PSC Research
  • Rare Diseases
  • Contact Us

Scientific Research
This page is in a'blog' format with the latest scientific PSC research identified by Google Scholar, Readbyqmx.com and other sources added regularly.

Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis

10/19/2015

0 Comments

 
Evangelos Kalaitzakis, Maria Benito de Valle, Monira Rahman, Björn Lindkvist, Einar Björnsson, Roger Chapman, Nick Kontodimopoulos

PURPOSE: 
The chronic liver disease questionnaire (CLDQ) is a frequently used liver-specific quality of life instrument, but it does not provide information on preference-adjusted health status, which is essential for cost-utility analysis. We aimed to develop a mapping function deriving utilities from the CLDQ in primary sclerosing cholangitis (PSC).

METHODS: 
​Short form-6D (SF-6D) utilities were calculated from SF-36 data collected in a recent prospective study in which unselected patients with PSC also completed the CLDQ ... please click here to read the abstract.

Quality of Life Research 2015 October 15
0 Comments

Ultrasound elastography

10/13/2015

0 Comments

 
R S Goertz
Der Radiologe 2015 October 5

Noninvasive, ultrasound-based methods for visualizing and measuring tissue elasticity are becoming more and more common in routine practice. Using hepatic shear wave elastography, cut-off levels can help to detect the degree of relevant fibrosis (F ≥ 2) with a diagnostic accuracy using the area under the reader operating characteristic (AUROC) of 87 % and cirrhosis (F = 4, AUROC 93 %). Normal values virtually exclude liver cirrhosis (negative predictive value up to 97 %) and high shear wave velocities predict complications in the course of primary sclerosing cholangitis ... please click here to read the remainder of the abstract
0 Comments

August 11th, 2015

8/11/2015

0 Comments

 
0 Comments

Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis

6/22/2014

0 Comments

 
Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis 

James H. Tabibian, Felicity Enders, Mohamad H. Imam, Gururaj Kolar,  Keith D. Lindor, Jayant A. Talwalkar.
Annals of Hepatology,  2014, May-June, Vol. 13 No. 3, 2014: 384-389

Abstract

Introduction: Primary sclerosing cholangitis (PSC) is an idiopathic hepatobiliary disorder associated with an increased risk for cholangiocarcinoma (CCA) and a median survival time of 12 years. Reliable predictors of CCA and other major adverse events in PSC are currently lacking. Recently, serum IgE was found to be as- sociated with CCA in a Japanese cohort of PSC patients. Our aim in this study was to determine whether IgE levels predict time to CCA, liver transplantation, or death in a Western (USA-based) cohort of PSC pa- tints. 

Material and methods: Thirty-eight patients with PSC and IgE levels were identified and categorized into low or high IgE groups based on the sample median. Groups were compared with respect to clinical characteristics and adverse endpoint-free survival . . . Please click here to be taken to the full text article

0 Comments

Normalization of Serum Alkaline Phosphatase in Primary Sclerosing Cholangitis Associated with Ulcerative Colitis 

4/21/2014

0 Comments

 

Normalization of Serum Alkaline Phosphatase in Primary Sclerosing Cholangitis Associated with Ulcerative Colitis 


Mitsuro Chiba, Hidehiko Tsuda, Satoko Tsuda, Masafumi Komatsu, Yasuo Horie, Hirohide Ohnishi

Abstract

Primary sclerosing cholangitis (PSC) is commonly associated with ulcerative colitis (UC). PSC progresses independently of UC ultimately resulting in liver failure. There is no established medi- cal treatment to improve the natural course of PSC. Normalization of serum alkaline phosphatase (ALP) in early stage might delay the progress of PSC. A 20-year-old female, had a sudden attack of right hypochondralgia with high fever and abnormal liver function tests without elevation of bili- rubin: ALP 478 IU/L, aspartate aminotransferase 360 IU/L, alanine aminotransferase 174 IU/L. Abnormal liver function tests returned to normal after the attacks. Morphological examinations initially indicated then confirmed a diagnosis of PSC. One month after displaying PSC symptoms administration of ursodeoxycholic acid was initiated. Similar attacks of cholangitis were repeated several times over the following two years. Even in the absence of these attacks, she always suf- fered postprandial hypochondralgia ... Full article available by clicking on the title

Copyright © 2014 by authors and Scientific Research Publishing Inc
This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/
0 Comments

Donor-transmitted, donor-derived, and de novo cancer after liver transplant.

4/2/2014

0 Comments

 
Donor-transmitted, donor-derived, and de novo cancer after liver transplant.

Chapman JR, Lynch SV., Exp Clin Transplant. 2014 Mar;12 Suppl 1:50-4.

Abstract

Cancer is the third most common cause of death (after cardiovascular disease and infection) for patients who have a functioning kidney allograft. Kidney and liver transplant recipients have similar cancer risks because of immunosuppression but different risks because of differences in primary diseases that cause renal and hepatic failure and the inherent behavior of cancers in the liver. 

There are 4 types of cancer that may develop in liverallograft recipients: (1) recurrent cancer, (2) donor-transmitted cancer, (3) donor-derived cancer, and (4) de novo cancer . . . To read further please click on the title.

0 Comments

Researchers explore transplanting stem cells to reduce inflammation in the liver

3/21/2014

0 Comments

 
Researchers explore transplanting stem cells to reduce inflammation in the liver

University of Birmingham researchers are to lead a worldwide collaboration of scientists looking at the possibility of transplanting stem cells from one person to another to reduce inflammation in the liver.

Prof Philip Newsome and Dr Gideon Hirschfield, from the University's School of Immunity and Infection, will lead the €5.4 million Mesenchymal stem cells (MSC) to Reduce Liver Inflammation (MERLIN) programme which will include the first clinical trial of mesenchymal stem cells in liver disease in the UK.

The EU-funded programme will study how mesenchymal stem cells can reduce inflammation in the liver of people suffering from primary sclerosing cholangitis (PSC), a disease which causes inflammation and thickening of the bile ducts, build-up of bile in the liver and life-threatening liver disease . . . To read further, please click on the title.

Provided by University of BirminghamReference: http://phys.org/wire-news/156668415/researchers-explore-transplanting-stem-cells-to-reduce-inflammat.html (accessed 22.03.14)
0 Comments

    Research

    Every effort is taken to ensure the research presented is from reputable sources. 

    In order to ensure that copyright is not breached, only a small portion of the abstract is provided here. Clicking on the title will take you to the original journal, or site, where the abstract has been published. Most times only an abstract of an article is available as subscriptions are usually required. Occasionally a full text is made freely available.

    RSS Feed

    News & Updates Blog
    Glossary

    Archives

    December 2016
    September 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    August 2014
    July 2014
    June 2014
    April 2014
    March 2014


    Categories

    All
    Adolescence
    Adults
    Antibiotic
    Australia
    Australian
    Autoimmune Diseases
    Autoimmune Hepatitis
    Bezafibrate
    Bile Leak
    Biliary Strictures
    Cancer
    CCA Risk
    Children
    Cholangiocarcinoma
    Cholangitis
    Cholectomy
    Cholestatic Liver Disease
    Colectomy
    Colorectal Cancer
    Consensus Statement
    Crohn's Disease
    Diagnosis
    Drug Therapy
    Endoscopy
    Environmental Factors
    ERCP
    Fibroscan
    Genetics
    Genomes
    Genotypes
    Hepatic Cholestasis
    HLA
    IBD
    IgE Levels
    IgG4
    Inflammatory Bowel Disease
    Itching
    Leaky Gut
    Liver
    Liver Tests
    Liver Transplant
    Living Donor
    Management Of PSC
    MELD Score
    Microbiome
    Organ Donation
    Outcomes
    Paediatric Patients
    Paediatric PSC
    Patient And Graft Survival
    Pets
    Population
    Prognosis
    Pruritus
    PSC
    PSC/AIH
    Quality Of Life
    Questionnaire
    Recurrent PSC
    RPSC
    Sclerosing Cholangitis
    Scoring Systems
    Screening
    Staging
    Staging Systems
    Stem Cells
    Stenosis
    Terminal Restriction Fragment (TRF)
    Treatment
    Ulcerative Colitis
    Ultrasound
    Ultrasound Elastography
    Ursodeoxycholic Acid
    Vancomycin


    RSS Feed


    Page created 09.03.2014
    Updated: 09.04.2014
Disclaimer:  The information presented on this website is intended for information and educational purposes only, and is not intended to be a substitute for medical advice or information in any way. The information is not written by a medical practitioner, and as such it should never be used for diagnostic, treatment or management purposes. If you have questions regarding your medical needs, always seek the advice of your doctor, specialist or other appropriate and qualified health care professional.
This is a non-commercial website, designed and developed to provide relevant information to people living with Primary Sclerosing Cholangitis.
Wallpaper by Gaiam   www.gaiam.com.au

Full Disclaimer
Medical Disclaimer


Privacy & Cookie Policy


Powered by Create your own unique website with customizable templates.

BACK TO TOP

PSC-Australia.com.au
©2014 Health & Education Services | All Rights Reserved

© DivTag Templates Ltd | All Rights Reserved